Zepbound and Sleep Apnea: What the SURMOUNT-OSA Trial Showed

In December 2024, Zepbound's FDA label expanded to cover moderate-to-severe obstructive sleep apnea in adults with obesity — the first drug ever approved specifically to treat OSA. Every prior FDA-cleared option for the condition has been a device (CPAP) or a surgical intervention. This is worth understanding on its own terms, not just as a footnote to Zepbound's weight-loss indication.

Two trials, not one

The approval rests on SURMOUNT-OSA, which was actually two separate phase 3, double-blind, randomized, placebo-controlled trials run in parallel — one enrolling adults with moderate-to-severe OSA and obesity who were not using positive airway pressure (PAP) therapy at baseline, the other enrolling adults who were already on PAP therapy¹. Participants in both trials received either the maximum tolerated dose of tirzepatide (10 mg or 15 mg) or placebo for 52 weeks. The primary endpoint in both was change in the apnea-hypopnea index (AHI) — the number of apneas and hypopneas per hour of sleep.

The actual numbers

At baseline, mean AHI was 51.5 events per hour in the non-PAP trial and 49.5 in the PAP trial — both in the severe range. At week 52:

- **Trial 1 (no baseline PAP use):** AHI fell by a mean of 25.3 events/hour with tirzepatide versus 5.3 with placebo — an estimated treatment difference of 20.0 events/hour fewer (95% CI, 14.2 to 25.8). - **Trial 2 (baseline PAP use):** AHI fell by a mean of 29.3 events/hour with tirzepatide versus 5.5 with placebo — a treatment difference of 23.8 events/hour fewer (95% CI, 17.9 to 29.6).

Both differences were statistically significant (P<0.001). Tirzepatide also produced significant improvements across every prespecified secondary endpoint: body weight, hypoxic burden, patient-reported sleep impairment and disturbance, high-sensitivity C-reactive protein, and systolic blood pressure. Adverse events were the same GI-predominant, mostly mild-to-moderate pattern covered in GLP-1 side effects — nothing OSA-specific turned up in the safety data.

Why obesity and OSA are connected in the first place

Excess adiposity is an established, direct risk factor for obstructive sleep apnea — fat deposits around the upper airway and neck narrow it mechanically, and abdominal fat reduces lung volume in ways that worsen airway collapse during sleep. That's the biological logic behind testing a weight-loss drug for a breathing disorder, and why the trial measured weight change as a secondary endpoint alongside AHI rather than treating them as unrelated outcomes.

What this doesn't mean

This is not a replacement for CPAP, and the trial itself didn't test it that way — one of the two SURMOUNT-OSA trials specifically enrolled patients who stayed on PAP therapy throughout and still showed a significant additional AHI reduction on top of it. Whether tirzepatide can eventually replace PAP therapy for some patients, rather than supplement it, is a question for a sleep specialist, not something this trial design was built to answer. If you have diagnosed or suspected OSA and obesity, this indication is worth raising directly with a sleep medicine provider alongside whatever GLP-1 provider you're evaluating.

Where this fits in the bigger picture

Zepbound's OSA approval is part of a pattern across this drug class — GLP-1 drugs have now picked up FDA indications well beyond the original weight-loss and diabetes uses, including cardiovascular risk reduction and kidney disease progression; see GLP-1, the heart and the kidneys for that evidence. For how Zepbound's tirzepatide compares to the drug it shares a molecule with, see Mounjaro vs Zepbound, and for the brand-vs-brand weight-loss comparison, Wegovy vs Zepbound. CoreAge Rx carries tirzepatide, and the tirzepatide board ranks the field; the rest of the Desk's sourced evidence is in the research library.